Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of California, San Diego FDA Office of Orphan Products Development Memgen, LLC |
---|---|
Information provided by: | University of California, San Diego |
ClinicalTrials.gov Identifier: | NCT00849524 |
This is a Phase II, open label, fixed dose, repeat injection, single institution study. Eligible subjects will receive up to six doses of Ad-ISF35 injected directly into a selected lymph node under ultrasound guidance. The primary goal is to determine and monitor clinical and biological responses in patients treated with repeat intranodal injections of Ad-ISF35.
Condition | Intervention | Phase |
---|---|---|
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma |
Biological: ISF35 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma |
Estimated Enrollment: | 28 |
Study Start Date: | January 2009 |
Estimated Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
This is a phase II clinical trial in which study subjects will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
Because this is the first time that repeat administration of Ad-ISF35 will be performed via intranodal injection, and in order to allow sufficient time to evaluate the safety and toxicity of this procedure, we will treat subjects 1 thru 3 at one month intervals and with inpatient admission for 24 hours observation. After subject three receives their second ISF35 injection we will proceed with enrollment of cohorts of four patients per month at one week intervals until study enrollment has been completed. These subjects will be treated as outpatients and will be observed for 3 hours prior to discharge.
ISF35 has already been used in Phase I clinical trials. The trials demonstrated that ISF35 treatment is well-tolerated and patients did not experience any significant or unexpected adverse events. Patients reported flu-like symptoms from ISF35, which disappeared within one to three days.
ISF35 is an abbreviation for Immune Stimulatory Factor 35, an offspring of technology discovered by Dr. Thomas J.
Kipps, MD, PhD, Professor, Department of Medicine and Deputy Director for Research,UCSD Moores Cancer Center.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Diagnosis of B-cell CLL/SLL including:
Indication for treatment as defined by the NCI Working Group Guidelines:
Laboratory parameters as specified below:
Exclusion Criteria:
Contact: Vineeta Prasad | (858) 822-0337 | vprasad@ucsd.edu |
United States, California | |
University of California, San Diego Moores Cancer Center | Recruiting |
La Jolla, California, United States, 92093 | |
Contact: Vineeta Prasad 858-822-0337 vprasad@ucsd.edu | |
Contact: Mary Carpenter (858) 822-5635 mcarpenter@ucsd.edu | |
Principal Investigator: Januario Castro, M.D. | |
Principal Investigator: Thomas J Kipps, M.D., Ph.D. |
Principal Investigator: | Januario Castro, M.D. | Associate Clinical Professor in the Blood and Marrow Transplantation Division |
Principal Investigator: | Thomas J Kipps, M.D., Ph.D. | Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research in the UCSD School of Medicine |
Responsible Party: | University of California, San Diego Moores Cancer Center ( University of California, San Diego Moores Cancer Center (Dr. Januario Castro, M.D./Associate Clinical Professor in the Blood and Marrow Transplantation Division) ) |
Study ID Numbers: | UCSD-080497, CLL-35-202 |
Study First Received: | February 20, 2009 |
Last Updated: | July 17, 2009 |
ClinicalTrials.gov Identifier: | NCT00849524 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Lymphatic Diseases Leukemia Chronic Lymphocytic Leukemia Leukemia, Lymphoid Immunoproliferative Disorders Leukemia, Lymphocytic, Chronic, B-Cell |
Adenoviridae Infections Leukemia, B-cell, Chronic Lymphoproliferative Disorders Leukemia, B-Cell Lymphoma |
Lymphatic Diseases Leukemia Neoplasms Leukemia, Lymphoid Immunoproliferative Disorders Neoplasms by Histologic Type |
Immune System Diseases Leukemia, Lymphocytic, Chronic, B-Cell Lymphoproliferative Disorders Leukemia, B-Cell Lymphoma |